GPC3 and hepatocellular carcinoma: The heparan sulfate proteoglycan GPC3 is an attractive target for drug development as it is highly upregulated in HCC and several pediatric solid embryonal tumors and is responsible for driving key growth and developmental pathways which are currently not effectively targeted using our existing therapies (2, 12, 78).